A venture capital firm actively invests in pre-seed and seed stage companies. Typical initial size of investment ranges from $1-1.5M. The firm focuses on the following areas: digital economy, climate & environment, health & well-being. The firm is strongly interested in companies based in North America and Latin America.
Historically, the firm has been agnostic towards technology area and indications. That said, the firm is currently interested in exploring opportunities in new modalities and biologics, and expanding their interests in peptide-based therapies and induced proximity therapeutics (i.e. molecular glues, PROTACs). The firm invests mainly in pre-clinical and early clinical therapeutics. The firm actively invests in therapeutics, diagnostics, and life science tools.
The firm seeks to work with exceptional entrepreneurs who are passionate about their work, and is open to working with first-time entrepreneurs. The firm’s investment process starts from an initial meeting and evaluating the opportunity, a decision analysis including the addressed market, life stages assessment, and a final assessment, and if choosing to move forward, proceeding with legal due diligence and signing/execution. To date, the firm has led about 50% of their deals, and following in the other half.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment